Processing

Please wait...

Settings

Settings

1. WO2000043014 - BETA-D-2',3'-DIDEHYDRO-2',3'-DIDEOXY-5-FLUOROCYTIDINE FOR USE IN THE TREATMENT OF HIV INFECTIONS

Publication Number WO/2000/043014
Publication Date 27.07.2000
International Application No. PCT/US2000/001738
International Filing Date 21.01.2000
Chapter 2 Demand Filed 08.08.2000
IPC
A61K 31/70 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
CPC
A61K 31/513
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
513having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/52
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
A61K 31/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants
  • EMORY UNIVERSITY [US/US]; 1380 S. Oxford Road Atlanta, GA 30322, US (AllExceptUS)
  • SCHINAZI, Raymond, F. [US/US]; US (UsOnly)
  • HAMMOND, Jennifer [US/US]; US (UsOnly)
  • MELLORS, John, W. [US/US]; US (UsOnly)
  • LIOTTA, Dennis, C. [US/US]; US (UsOnly)
Inventors
  • SCHINAZI, Raymond, F.; US
  • HAMMOND, Jennifer; US
  • MELLORS, John, W.; US
  • LIOTTA, Dennis, C.; US
Agents
  • KNOWLES, Sherry, M.; King & Spalding 191 Peachtree Street Atlanta, GA 30303-1763, US
Priority Data
60/116,77322.01.1999US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BETA-D-2',3'-DIDEHYDRO-2',3'-DIDEOXY-5-FLUOROCYTIDINE FOR USE IN THE TREATMENT OF HIV INFECTIONS
(FR) MUTATIONS DE VIH-1 SELECTIONNEES A L'AIDE DE $g(b)-2',3'-DIDEHYDRO-2',3'-DIDEOXY-5-FLUOROCYTIDINE
Abstract
(EN)
The present invention discloses a method for treating HIV that includes administering $g(b)-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or the 172 codons of the reverse transcriptase region. Also disclosed is a method for using $g(b)-D-D4FC as 'salvage therapy' to patients which exhibit drug resistance to other anti-HIV agents. $g(b)-D-D4FC can be used generally as salvage therapy for any patient which exhibits resistance to a drug that induces a mutation at other than the 70(K to N), 90 or the 172 codons.
(FR)
On décrit un procédé de traitement du VIH-1 qui consiste à administrer du $g(b)-D-D4FC ou un sel pharmaceutiquement acceptable de ce dernier ou encore un promédicament contenant ce dernier à un humain nécessitant une thérapie en combinaison ou en alternance avec un médicament qui induit une mutation du VIH-1 à un endroit autre que les 70 (K à N), 90 ou 172 codons de la région de transcriptase inverse. On décrit également un procédé d'utilisation de $g(b)-D-D4FC en tant que 'thérapie sauvage'' chez des patients présentant une résistance médicamenteuse à d'autres agents anti-VIH. Le $g(b)-D-D4FC peut être utilisé de manière générale en tant que thérapie sauvage pour n'importe quel patient présentant une résistance à un médicament qui induit une mutation à un autre endroit que les codons 70 (K à N), 90 ou 172.
Other related publications
Latest bibliographic data on file with the International Bureau